Chitosan based atorvastatin nanocrystals: effect of cationic charge on particle size, formulation stability, and in-vivo efficacy

References

• KidaneABhattPPRecent advances in small molecule drug deliveryCurr Opin Chem Biol20059434735116006179
   PubMed Web of Science ®Google Scholar
• WangBSiahaanTJSolteroRADrug delivery: principles and applicationsNew JerseyJohn Wiley and Sons2005
   Google Scholar
• WilliamsHDTrevaskisNLCharmanSAStrategies to Address Low Drug Solubility in Discovery and DevelopmentPharmacol Rev201365113151499
   Google Scholar
• LiversidgeGGConzentinoPDrug particle size reduction for decreasing gastric irritancy and enhancing absorption of naproxen in ratsInt J Pharm19951252309313
   Google Scholar
• KasimNAWhitehouseMRamachandranCMolecular Properties of WHO Essential Drugs and Provisional Biopharmaceutical ClassificationMol Pharm200411859615832504
   PubMed Web of Science ®Google Scholar
• CillaDDJrWhitfieldLRGibsonDMSedmanAJPosvarELMultiple-dose pharmacokinetics, pharmacodynamics, and safety of atorvastatin, an inhibitor of HMG-CoA reductase, in healthy subjectsClin Pharmacol Ther19966066876958988072
   PubMedGoogle Scholar
• LawMRWaldNJRudnickaARQuantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysisBMJ20033267404142312829554
   PubMed Web of Science ®Google Scholar
• KimJSKimMSParkHJJinSJLeeSHwangSJPhysicochemical properties and oral bioavailability of amorphous atorvastatin hemi-calcium using spray-drying and SAS processInt J Pharm20083591–221121918501538
   PubMed Web of Science ®Google Scholar
• LauHHOkochiHHuangYBenetLZPharmacokinetics of atorvastatin and its hydroxymetabolites in rats and the effects of concomitant rifampicin single doses: relevance of first-pass effect from hepatic uptake transporters, and intestinal and hepatic metabolismDrug Metab Dispos20063471175118116624870
   PubMedGoogle Scholar
• LennernasHHuman jejunal effective permeability and its correlation with preclinical drug absorption modelsJ Pharm Pharmacol19974976276389255703
   PubMedGoogle Scholar
• LennernasHClinical pharmacokinetics of atorvastatinClin Pharmacokinet200342131141116014531725
   PubMed Web of Science ®Google Scholar
• KaduPJKushareSSThackerDDGattaniSGEnhancement of oral bioavailability of atorvastatin calcium by self-emulsifying drug delivery systems (SEDDS)Pharm Dev Technol2011161657420088679
   PubMed Web of Science ®Google Scholar
• ShenHZhongMPreparation and evaluation of self-micro emulsifying drug delivery systems (SMEDDS) containing atorvastatinJ Pharm and Pharmcol200658911831191
   PubMed Web of Science ®Google Scholar
• MiryalaVKurakulaMSelf-nano emulsifying drug delivery systems (SNEDDS) for oral delivery of atorvastatin -formulation and bioavailability studiesJ Drug Deliv Therap20133131142
   Google Scholar
• KimMJinSKimJPreparation, characterization and in vivo evaluation of amorphous atorvastatin calcium nanoparticles using supercritical antisolvent (SAS) processEur J Pharm Biopharm200869245446518359211
   PubMed Web of Science ®Google Scholar
• ZhangHXWangJXZhangZBLeYShenZGChenJFMicronization of atorvastatin calcium by antisolvent precipitation processInt J Pharm20093741–210611319446766
   PubMed Web of Science ®Google Scholar
• JunghannsJUMullerRHNanocrystal technology drug delivery and clinical applicationsInt J Nanomedicine20083329531018990939
   PubMed Web of Science ®Google Scholar
• MoschwitzerJPDrug nanocrystals in the commercial pharmaceutical development processInt J Pharm2013453114215623000841
   PubMed Web of Science ®Google Scholar
• KeckCMMullerRHDrug nanocrystals of poorly soluble drugs produced by high pressure homogenisationEur J Pharm Biopharm200662131616129588
   PubMed Web of Science ®Google Scholar
• CrispMTTuckerCJRogersTLWilliamRO3rdJohnstonKPTurbidimetric measurement and prediction of dissolution rate of poor soluble drug nanocrystalsJ Control Release2007117335135917239469
   PubMed Web of Science ®Google Scholar
• JinnoJKamadaNMiyakiMEffect of particle size reduction on dissolution and oral absorption of poor soluble drugsJ Control Release20061111–2566416410029
   PubMed Web of Science ®Google Scholar
• DelongeasJLVermeil de ConchardGBeamonteAAssessment Labrasol/Labrafil/Transcutol (4/4/2, v/v/v) as a non-clinical vehicle for poorly water-soluble compounds after 4-week oral toxicity study in Wistar ratsRegul Toxicol Pharm2010572–3284290
   Google Scholar
• SunWTianWZhangYHeJMaoSFangLEffect of novel stabilizers cationic polymers on the particle size and physical stability of poorly soluble drug nanocrystalsNanomedicine20128446046721839057
   PubMedGoogle Scholar
• MuzzarelliRAHuman enzymatic activities related to therapeutic administration of chitin derivativesCell Mol Life Sci19975321311409118001
   PubMed Web of Science ®Google Scholar
• HiranoSSeinoHAkiyamaYNonakaIChitosan: a biocompatible material for oral and intravenous administration, in Oral and Intravenous AdministrationsProgress in Biomedical Polymers1990283289
   Google Scholar
• MaoSSunWKisselTChitosan-based formulations for delivery of DNA and siRNAAdv Drug Deliv Rev2010621122719796660
   PubMed Web of Science ®Google Scholar
• MaoSShuaiXUngerFSimonMBiDKisselTThe depolymerisation of chitosan: effects on physiochemical and biological propertiesInt J Pharm20042811–2455415288342
   PubMedGoogle Scholar
• LeeEKimHLeeIHJonSIn vivo antitumor effects of chitosan-conjugated docetaxel after oral administrationJ Control Release20091402798519712714
   PubMed Web of Science ®Google Scholar
• LeeELeeJLeeIHConjugated chitosan as a novel platform for oral delivery of paclitaxelJ Med Chem200851206442644918826299
   PubMed Web of Science ®Google Scholar
• Dos SantosSMedronhoBSantosTDAntunesFEAmphiphilic Molecules in Drug Delivery SystemsAdvan Pred Preven Person Med2013435485
   Google Scholar
• LuYWangZHLiTNallyHMParkKSturekMDevelopment and evaluation of transferrin-stabilized paclitaxel nanocrystal formulationJ Control Release2014176768524378441
   PubMed Web of Science ®Google Scholar
• FuQSunJAiXNimodipine nanocrystals for oral bioavailability improvement: Role of mesenteric lymph transport in the oral absorptionInt J Pharm2013448129029723384726
   PubMedGoogle Scholar
• ChaudharyHRBrocksDRThe single dose poloxamer 407 model of hyperlipidemia; systemic effects on lipids assessed using pharmacokinetic methods, and its effects on adipokinesJ Pharm Pharm Sci2013161657323683606
   PubMedGoogle Scholar
• International Conference on Harmonization [homepage on the Internet]ICH Harmonized Tripartite guidelineValidation of Analytical Procedures: Text and Methodology Q2 (R1)Current Step 4 version. Parent Guideline dated 27 October 1994(Complementary Guideline on Methodology dated 6 November 1996; incorporated in November 2005) Available from: http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q2_R1/Step4/Q2_R1__Guideline.pdfAccessed December 11, 2014
   Google Scholar
• KurakulaMSobahiTREl-HelwAMAbdelaalMYDevelopment and Validation of a RP-HPLC Method for Assay of Atorvastatin and its Application in Dissolution Studies on Thermosensitive Hydrogel-Based NanocrystalsTrop J Pharm Res2014131016811687
   Google Scholar
• International Conference on Harmonization [homepage on the Internet]ICH Harmonized Tripartite guidelineQ1A (R2) Stability Testing of New Drug Substances and Products Step 42003 Available from: http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q1A_R2/Step4/Q1A_R2__Guideline.pdfAccessed December 11, 2014
   Google Scholar